The ASX IPO crash of 2018

Published 13-DEC-2018 16:49 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Let’s not beat around the bush. Initial Public Offerings, otherwise known as IPOs, have been off the boil this year.

In fact, the listing landscape has been brutal across the board.

According to research conducted by EverBlu Capital, many investors are nursing double digit losses, with the average loss coming in around 31.5% and the median loss holding firm at 17.9%.

EverBlu’s 2018 IPO Report includes some damning statistics.

There have been 86 IPOs (or RTOs) this year and only 19 of the 86 show positive returns; 65 show negative returns; and two are flat.

Further, a total of A$8.053 billion was raised and the loss so far on the amount raised is $1.324 billion. The two largest listings — Coronado Global and Viva Energy are down 25% and 24% respectively.

The report, prepared by EverBlu’s Russell Wright, gives a comprehensive list of IPOs in 2018. Here’s a quick look at the top and bottom five performers.

The ASX has not been a happy place for companies looking to IPO

You can view the full report here.

A couple of reasons IPOs have failed this year

When it comes to successful listings, a comparison between 2017 and 2018 is stark.

2017 was actually a bumper year and according to Deloitte, there were 57 listings just in the six months to June — compared with 40 in the same period this year.

According to the annual On market Report released in February this year, small-cap listings powered IPOs in Australia to a 61.6% average return in 2017.

Business Insider Australia gave us this gem of an infographic highlighting 2017's IPOs by sector.

IPO by sector in 2017.

Clearly, all was pretty rosy last year. So what happened in 2018?

One issue is poor communication: a failure to communicate the message to investors and help them understand the company’s position and its objectives.

It is as Ben Heap founding partner of venture capital firm H2 Ventures told CRN: “IPO’ing means, as a high-growth business, you have a significant communications challenge to ensure that the investors understand where the company is at and what its objectives are and how they’re trying to deliver.

"I think that companies that list too early face the challenge of a misalignment of expectations that private companies don’t have to deal with,” Heap says.

A broader look at the ASX from a macro level

The China-US trade war has also had a major ripple effect on international business, which has trickled down to Australian companies who have listed or were/are looking to do so.

Ringo Choi, the Asia Pacific IPO Leader of Ernst & Young said, "For the short term, I think it (the trade war) will affect the market and that will consequently affect the IPO."

At the time the trade war began, not only did the Australian dollar fall but according to the Australian Financial Review: “Tensions spooked investors. The local S&P/ASX 200 index fell 23.5 points, or 0.4%, to 6161.5, following Wall Street's weak market close as anticipation of the tariffs rose in late trading.”

Suffice to say, it’s been a tough market ever since. However, according to the same publication:

Could the ASX see uplift in 2019?

Given the fluctuations we have seen in 2018, it is difficult to determine what will happen to aspiring IPO'ers in the next 12 months.

Assuming global tensions settle, private companies don’t list before they’re ready — and they communicate their proposition to the market effectively — we are unlikely to see the degree of failure in 2019.

Yet, as with all things, only time will tell.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X